SWITCH: Apixaban vs Vitamin K in HM3
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 460 participants.
Also called NCT07471139
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 460 participants
- Sponsor
- Registry
-
NCT07471139
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07471139. Randomized; no masking; primary purpose treatment. Start 2026-10-15 (actual); primary completion 2029-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SWITCH: Apixaban vs Vitamin K in HM3
- Condition
- LVAD (Left Ventricular Assist Device) Thrombosis
- Condition
- Heart Failure
- Condition
- Bleeding
- Condition
- Thrombosis; Artery
- Condition
- Stroke
- Condition
- Heart Transplant
- Intervention (Drug)
- Warfarin
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Columbia University
Record details
- Record id
cardio:ct-nct07471139- Content hash
61b29ef718d33041250e5949c14b2f6920823643b6b7ca2b054985597113bf24